Skip to content

The clinical observation of the therapeutic effect of Ningyun Yiya Yin in Hypertensive vertigo

The clinical observation of the therapeutic effect of Ningyun Yiya Yin in Hypertensive vertigo

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089706
Enrollment
Unknown
Registered
2024-09-13
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive vertigo

Interventions

Control group:Conventional Treatment for Hypertension-Induced Vertigo, includes appropriate exercise, controlled diet, smoking and alcohol cessation, and medication.
Experimental group:Conventional Treatment for Hypertension-Induced Vertigo and taking Ningyun Yiya Yin.

Sponsors

Jiangsu Province Hospital of Integration of Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria of hypertension in Western medicine and the diagnostic criteria of syndromes in traditional Chinese medicine: dizziness, wind-dampness disturbance type; 2. Aged between 18 and 65; 3. The primary observation object is I and II stage hypertension; 4. Essential hypertension, measured blood pressure three times on different days within one week, reaching the diagnostic standard; 5. No Chinese or Western medicine for dizziness treatment taken within one month before treatment; 6. Informed consent and voluntary participation by patients.

Exclusion criteria

Exclusion criteria: 1. Under the age of 18 or over 65; pregnant or lactating women. 2. Hypertensive crisis or secondary hypertension; or with serious primary diseases of heart, brain, liver, kidney, and hematopoietic system; or mentally ill patients; 3. Allergic constitution or patients allergic to multiple drugs; 4. Unconscious, cognitive impairment, or patients who refuse to cooperate.

Design outcomes

Primary

MeasureTime frame
Blood pressure;Routine blood;Electrocardiogram;Chinese medicine symptom complex score;Adverse events;DARS;

Secondary

MeasureTime frame
Renal function;Liver function;

Countries

China

Contacts

Public ContactWang Xindong

Jiangsu Province Hospital of Integration of Chinese and Western Medicine

wangxindong@jsatcm.com+86 136 5518 8838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026